Tenet Healthcare (NYSE:THC) Price Target Raised to $283.00

Tenet Healthcare (NYSE:THC) had its price objective hoisted by Guggenheim from $242.00 to $283.00 in a research note released on Tuesday, Marketbeat.com reports. Guggenheim currently has a buy rating on the stock.

THC has been the subject of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Tenet Healthcare in a research report on Monday. Robert W. Baird upped their target price on shares of Tenet Healthcare from $210.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday. Morgan Stanley raised their price target on shares of Tenet Healthcare from $254.00 to $274.00 and gave the stock an “overweight” rating in a research report on Monday. Wells Fargo & Company boosted their price objective on shares of Tenet Healthcare from $213.00 to $231.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, KeyCorp reduced their target price on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $268.50.

Tenet Healthcare Trading Down 1.9%

Shares of NYSE:THC opened at $252.80 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $21.78 billion, a PE ratio of 9.75, a P/E/G ratio of 0.98 and a beta of 1.27. Tenet Healthcare has a 1 year low of $156.71 and a 1 year high of $262.68. The firm has a fifty day moving average price of $190.49 and a 200 day moving average price of $198.96.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, beating analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The business had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same period last year, the business earned $4.02 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Analysts expect that Tenet Healthcare will post 21.09 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Christopher S. Lynch sold 3,837 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.44, for a total value of $934,079.28. Following the sale, the director owned 9,568 shares in the company, valued at approximately $2,329,233.92. The trade was a 28.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paola M. Arbour sold 10,878 shares of the company’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $243.90, for a total transaction of $2,653,144.20. Following the completion of the sale, the executive vice president directly owned 18,413 shares in the company, valued at approximately $4,490,930.70. The trade was a 37.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,353 shares of company stock valued at $5,103,217 in the last ninety days. Insiders own 0.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in Tenet Healthcare by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company’s stock worth $1,488,484,000 after acquiring an additional 119,809 shares during the last quarter. Boston Partners raised its position in Tenet Healthcare by 15.7% in the 4th quarter. Boston Partners now owns 3,642,136 shares of the company’s stock valued at $723,804,000 after purchasing an additional 494,581 shares during the last quarter. AQR Capital Management LLC boosted its stake in Tenet Healthcare by 20.3% in the fourth quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company’s stock worth $448,419,000 after purchasing an additional 380,116 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Tenet Healthcare by 8.0% in the second quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock valued at $373,020,000 after buying an additional 157,109 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Tenet Healthcare in the fourth quarter valued at about $248,494,000. 95.44% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Analysts raised their price targets: Truist lifted its target to $290, while Guggenheim increased its target to $283 and Robert W. Baird raised its target to $280. The revisions reflect growing confidence in Tenet’s earnings outlook and imply additional upside from recent trading levels. Truist raises Tenet Healthcare price target Baird analyst comments on Tenet Healthcare Guggenheim analyst comments on Tenet Healthcare
• Positive Sentiment: Growth and momentum remain key attractions: Zacks highlighted Tenet’s above-average financial growth, strong momentum characteristics and potential appeal to growth-focused investors. These reports may support continued retail and quantitative-investor interest in THC. Three reasons growth investors may like Tenet Healthcare Tenet Healthcare momentum analysis
• Positive Sentiment: Fundamental performance supports the bullish case: Tenet’s latest quarterly results exceeded estimates, with EPS of $6.12 versus a $4.26 consensus and revenue of $6.04 billion versus $5.43 billion expected. The company also raised its 2026 outlook, strengthening the investment case behind the recent rally.
• Neutral Sentiment: Investor attention is elevated: Zacks reported increased user interest in Tenet and noted that the stock recently reached a 52-week high. However, the coverage is largely informational and does not represent a new company announcement or change in fundamentals. Zacks analysis of investor attention on Tenet Healthcare
• Negative Sentiment: Insider selling creates a modest overhang: EVP Paola Arbour sold 10,878 shares for approximately $2.65 million, while Director Christopher Lynch sold 3,837 shares worth about $934,000. Both transactions significantly reduced their holdings, although the sales may reflect personal financial planning rather than a negative view of Tenet’s prospects.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.